Corcept Therapeutics shares sink after losing patent infringement lawsuit against TevaProactive Investors • 01/02/24
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and AsthmaBusiness Wire • 12/14/23
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid ObesityBusiness Wire • 12/06/23
Teva Pharmaceutical Industries Limited (TEVA) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)Seeking Alpha • 11/28/23
Teva Pharmaceutical analysts boost target price as brand transition underwayProactive Investors • 11/27/23
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.Business Wire • 11/17/23
MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)Business Wire • 11/13/23
Teva Pharmaceuticals says production is largely unaffected from Israel-Hamas conflict, raises guidanceProactive Investors • 11/08/23
Teva Pharmaceutical Industries Ltd. (TEVA) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/08/23
Teva Closes In On A Buy Point On Third-Quarter Beat, Business SeparationInvestors Business Daily • 11/08/23
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue GuidanceBusiness Wire • 11/08/23